Skip to content
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
SV
Video presentations
December 6, 2023
CombiGene at Carlsquare Nordic life science investor day (only in Swedish)
September 20, 2023
CEO Peter Ekolind at BioStock Investor Meeting (only in Swedish)
August 25, 2023
CombiGene’s CEO gives a status update. Jan Nilsson visited BioStock’s studio to talk about the company’s second quarter.
Show more
Interviews & Articles
15 November, 2023
CombiGene focuses on the pain project
1 November, 2023
CombiGene has chosen CRO for the pain project
16 October, 2023
CombiGene’s CEO on the terminated collaboration with Spark
Show more
Stories
CombiGene Scientist Esbjörn Melin recently attended the 35th International Epilepsy Congress in Dublin Ireland
4th Gene Therapy for Neurological Disorders Europe in Amsterdam
ASGCT 2023 conference in Los Angeles, USA
Show more
